by Richard Daverman, PhD
May 22, 2014 -- Crown Bioscience closed a $26.6 million Series D funding round led by Lilly Asia Ventures Fund II. CrownBio is a preclinical CRO, specializing in oncology and metabolic disorders, headquartered in California with labs in Beijing, Taicang, the UK and North Carolina. CrownBio said it would use the money to expand its platform technologies and make acquisitions. More details....
Help employers find you! Check out all the jobs and post your resume.
